JP5702911B2 - トリアジン誘導体およびインスリン分泌促進剤の組合せ - Google Patents

トリアジン誘導体およびインスリン分泌促進剤の組合せ Download PDF

Info

Publication number
JP5702911B2
JP5702911B2 JP2008549780A JP2008549780A JP5702911B2 JP 5702911 B2 JP5702911 B2 JP 5702911B2 JP 2008549780 A JP2008549780 A JP 2008549780A JP 2008549780 A JP2008549780 A JP 2008549780A JP 5702911 B2 JP5702911 B2 JP 5702911B2
Authority
JP
Japan
Prior art keywords
formula
pharmaceutical composition
alkoxy
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008549780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523139A (ja
JP2009523139A5 (https=
Inventor
モワネ、　ジェラール
ジェラール モワネ、
ダニエル クラヴォ、
ダニエル クラヴォ、
ディディェ メサンジョ、
ディディェ メサンジョ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of JP2009523139A publication Critical patent/JP2009523139A/ja
Publication of JP2009523139A5 publication Critical patent/JP2009523139A5/ja
Application granted granted Critical
Publication of JP5702911B2 publication Critical patent/JP5702911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008549780A 2006-01-13 2006-12-18 トリアジン誘導体およびインスリン分泌促進剤の組合せ Active JP5702911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR06/00342 2006-01-13
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
PCT/EP2006/012182 WO2007079914A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators

Publications (3)

Publication Number Publication Date
JP2009523139A JP2009523139A (ja) 2009-06-18
JP2009523139A5 JP2009523139A5 (https=) 2010-02-12
JP5702911B2 true JP5702911B2 (ja) 2015-04-15

Family

ID=36648317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549780A Active JP5702911B2 (ja) 2006-01-13 2006-12-18 トリアジン誘導体およびインスリン分泌促進剤の組合せ

Country Status (21)

Country Link
US (1) US8227465B2 (https=)
EP (1) EP1971339B1 (https=)
JP (1) JP5702911B2 (https=)
KR (1) KR20080091366A (https=)
CN (1) CN101355949A (https=)
AR (1) AR059030A1 (https=)
AT (1) ATE540682T1 (https=)
AU (1) AU2006334731B2 (https=)
BR (1) BRPI0620923A2 (https=)
CA (1) CA2636837C (https=)
CY (1) CY1112674T1 (https=)
DK (1) DK1971339T3 (https=)
EA (1) EA016649B1 (https=)
ES (1) ES2378469T3 (https=)
FR (1) FR2896157B1 (https=)
IL (1) IL192596A (https=)
PL (1) PL1971339T3 (https=)
PT (1) PT1971339E (https=)
SI (1) SI1971339T1 (https=)
WO (1) WO2007079914A2 (https=)
ZA (1) ZA200806938B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923373B8 (pt) * 2008-12-12 2021-05-25 Merck Patent Gmbh composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
RU2550798C2 (ru) * 2011-05-12 2015-05-10 Василий Иосифович Зоря Способ стимуляции секреции инсулина
FR2987268B1 (fr) * 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
CA3078163A1 (en) 2017-10-02 2019-04-11 Poxel Methods of treating heart failure with preserved ejection fraction
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
AU2019286326A1 (en) * 2018-06-14 2020-12-10 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
USD945167S1 (en) 2018-10-31 2022-03-08 Kimberly-Clark Worldwide, Inc. Paper sheet
JP7093473B2 (ja) * 2019-12-13 2022-06-29 住友ファーマ株式会社 製造性及び溶出性に優れた小型錠剤
US12280125B2 (en) 2022-09-09 2025-04-22 Imam Abdulrahman Bin Faisal University Method for delivering insulin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
USRE40876E1 (en) * 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
ITFI20010126A1 (it) 2001-07-09 2003-01-09 Molteni & C Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide
ATE361065T1 (de) * 2002-01-25 2007-05-15 Silanes Sa De Cv Lab Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
KR20060119927A (ko) * 2003-09-02 2006-11-24 프로시디온 리미티드 혈당 조절을 위한 조합 요법

Also Published As

Publication number Publication date
EA200801665A1 (ru) 2008-12-30
JP2009523139A (ja) 2009-06-18
ES2378469T3 (es) 2012-04-12
IL192596A0 (en) 2009-09-22
US8227465B2 (en) 2012-07-24
WO2007079914A3 (en) 2007-09-07
EA016649B1 (ru) 2012-06-29
AU2006334731A1 (en) 2007-07-19
ZA200806938B (en) 2010-02-24
KR20080091366A (ko) 2008-10-10
CA2636837A1 (en) 2007-07-19
IL192596A (en) 2015-07-30
AU2006334731B2 (en) 2012-06-21
DK1971339T3 (da) 2012-02-20
WO2007079914A2 (en) 2007-07-19
BRPI0620923A2 (pt) 2011-11-29
CA2636837C (en) 2013-12-10
SI1971339T1 (sl) 2012-07-31
CN101355949A (zh) 2009-01-28
AR059030A1 (es) 2008-03-12
CY1112674T1 (el) 2016-02-10
US20100233255A1 (en) 2010-09-16
ATE540682T1 (de) 2012-01-15
EP1971339A2 (en) 2008-09-24
PL1971339T3 (pl) 2012-04-30
FR2896157A1 (fr) 2007-07-20
EP1971339B1 (en) 2012-01-11
FR2896157B1 (fr) 2008-09-12
PT1971339E (pt) 2012-02-20

Similar Documents

Publication Publication Date Title
JP5707490B2 (ja) ２型糖尿病の処置
JP5702911B2 (ja) トリアジン誘導体およびインスリン分泌促進剤の組合せ
AU2020309816B2 (en) Combination therapy of GPR119 agonists and DPP-4 inhibitors
US20140050786A1 (en) Combination of triazine derivatives and insulin sensitisers
JPWO2011002001A1 (ja) ピラゾール誘導体とビグアナイド薬との組み合わせ医薬
JP2009523141A (ja) トリアジン誘導体およびＨＭＧ−ＣｏＡレダクターゼ阻害剤の組合せ
WO2010050422A1 (ja) 糖尿病治療剤
HK1128405A (en) Combination of triazine derivatives and insulin secretion stimulators
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators
JP2009523143A (ja) トリアジン誘導体およびＰＰＡＲα作動薬の組合せ
HK1128232A (en) Combination of triazine derivatives and insulin sensitisers
MX2008008895A (en) Combination of triazine derivatives and insulin sensitisers
HK1128233A (en) COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20130404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130426

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130517

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140409

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20140821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150223

R150 Certificate of patent or registration of utility model

Ref document number: 5702911

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250